Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Mar;23(3):280-281.
doi: 10.1016/S1473-3099(23)00051-8. Epub 2023 Jan 31.

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant

Keiya Uriu  1 , Jumpei Ito  2 , Jiri Zahradnik  3 , Shigeru Fujita  1 , Yusuke Kosugi  1 , Gideon Schreiber  4 ; Genotype to Phenotype Japan (G2P-Japan) Consortium; Kei Sato  5
Affiliations

Enhanced transmissibility, infectivity, and immune resistance of the SARS-CoV-2 omicron XBB.1.5 variant

Keiya Uriu et al. Lancet Infect Dis. 2023 Mar.
No abstract available

PubMed Disclaimer

Conflict of interest statement

We declare no competing interests. KU and JI contributed equally. Supported in part by AMED SCARDA Japan Initiative for World-leading Vaccine Research and Development Centers UTOPIA (JP223fa627001, to KS), AMED SCARDA Program on R&D of new generation vaccine including new modality application (JP223fa727002, to Kei Sato); AMED Research Program on Emerging and Re-emerging Infectious Diseases (JP22fk0108146, to Kei Sato; JP21fk0108494 to G2P-Japan Consortium and Kei Sato; JP21fk0108425, to Kei Sato; JP21fk0108432, to Kei Sato); AMED Research Program on HIV/AIDS (JP22fk0410039, to Kei Sato); JST PRESTO (JPMJPR22R1, to Jumpei Ito); JST CREST (JPMJCR20H4, to Kei Sato); JSPS KAKENHI Grant-in-Aid for Early-Career Scientists (20K15767, Jumpei Ito); JSPS Core-to-Core Program (A. Advanced Research Networks) (JPJSCCA20190008, Kei Sato); JSPS Research Fellow DC2 (22J11578, to Keiya Uriu); The Tokyo Biochemical Research Foundation (to Kei Sato); and the project of National Institute of Virology and Bacteriology, Programme EXCELES, funded by the European Union, Next Generation EU (LX22NPO5103, to Jiri Zahradnik).

References

    1. Ito J, Suzuki R, Uriu K, et al. Convergent evolution of the SARS-CoV-2 Omicron subvariants leading to the emergence of BQ.1·1 variant. bioRxiv. 2022 doi: 10.1101/2022.12.05.519085. published online Dec 5. (preprint). - DOI - PMC - PubMed
    1. Tamura T, Ito J, Uriu K, et al. Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants. bioRxiv. 2022 doi: 10.1101/2022.12.27.521986. published online Dec 27. (preprint). - DOI - PMC - PubMed
    1. Yamasoba D, Kimura I, Nasser H, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. Cell. 2022;185:2103–2115. - PMC - PubMed
    1. Yamasoba D, Kosugi Y, Kimura I, et al. Neutralisation sensitivity of SARS-CoV-2 omicron subvariants to therapeutic monoclonal antibodies. Lancet Infect Dis. 2022;22:942–943. - PMC - PubMed
    1. Kimura I, Yamasoba D, Tamura T, et al. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. Cell. 2022;185:3992–4007. - PMC - PubMed

Publication types